Marta Gil-Martín

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji, Carla M.L. van Herpen, Cristina Saura et al. · The Lancet Oncology · 2019 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study

Dejan Juric, Jordi Rodón, Josep Tabernero et al. · Journal of Clinical Oncology · 2018 · 439 citations

Medicine, Oncology, Pharmacology +14

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12

Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

Dejan Juric, Filip Jankú, Jordi Rodón et al. · JAMA Oncology · 2018 · 260 citations · Full text

Medicine, Oncology, Pharmacology +15